Sub Banner Image

Novo Soars as Lilly’s Obesity Pill Result Offers Rare Relief

Markets

Naomi Kresge

·

August 7, 2025

·

Bloomberg

Novo Nordisk A/S shares soared as disappointing data from rival Eli Lilly & Co.’s closely watched obesity pill bolstered investor hopes about the Danish drugmaker’s ability to compete in the burgeoning market.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.